Key takeaways for New Mexico
- • No GLP-1 is FDA-approved for PCOS — entirely off-label.
- • BMI 27+ may qualify under standard Wegovy/Zepbound labels if comorbidities present.
- • Improvements seen in insulin resistance, weight, and androgens; fertility data limited.
- • Centennial Care coverage rules apply for PCOS (Polycystic Ovary Syndrome) patients in New Mexico — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for PCOS (Polycystic Ovary Syndrome)
No GLP-1 is FDA-approved specifically for PCOS. However, small randomized trials and observational studies show GLP-1 RAs improve insulin sensitivity, support 5-15% weight loss, reduce free testosterone, and may improve menstrual regularity and ovulation. Evidence grade: C-B (smaller trials, growing evidence base). PCOS guidelines (ESHRE/Monash 2023) recognize obesity-targeted pharmacotherapy as adjunct. Patients trying to conceive should stop GLP-1s at least 2 months before pregnancy attempts.
New Mexico-specific context
New Mexico has telehealth access concentrated in Albuquerque, Las Cruces, Rio Rancho metros, with additional reach to Santa Fe and Roswell. University of New Mexico Health, Presbyterian Healthcare Services is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.nmhealth.org.
New Mexicotelehealth & pricing rules
- • New Mexico permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • New Mexico allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New Mexico: ~$245/mo (compounded options often lower, brand higher).